Copyright Reports & Markets. All rights reserved.

Electroceutical Devices Global Market – Forecast To 2022

Request for Sample of this report
Buy now

1 EXECUTIVE SUMMARY 28

    2 INTRODUCTION 33

    • 2.1 KEY TAKEAWAYS 33
    • 2.2 REPORT DESCRIPTION 34
    • 2.3 MARKETS COVERED 35
    • 2.4 STAKEHOLDERS 37
    • 2.5 RESEARCH METHODOLOGY 37
      • 2.5.1 MARKET SIZE ESTIMATION 39
      • 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 41
      • 2.5.3 SECONDARY SOURCES 42
      • 2.5.4 PRIMARY SOURCES 42
      • 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 43
      • 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 44
      • 2.5.7 ASSUMPTIONS 44

    3 MARKET ANALYSIS 46

    • 3.1 INTRODUCTION 46
    • 3.2 MARKET SEGMENTATION 47
    • 3.3 FACTORS INFLUENCING MARKET 49
      • 3.3.1 DRIVERS AND OPPORTUNITIES 50
        • 3.3.1.1 Emergence of electroceuticals as a standalone therapy 50
        • 3.3.1.2 Increasing r & d investments for electroceuticals research 50
        • 3.3.1.3 Increasing aging population prone to neurological diseases 51
        • 3.3.1.4 Cost effective and can be withdrawn when adverse effect is seen 52
      • 3.3.2 RESTRAINTS AND THREATS 53
        • 3.3.2.1 Side effects and risks associated with the use 53
        • 3.3.2.2 Availability of alternative treatments 53
        • 3.3.2.3 Lack of trained professionals 54
    • 3.4 REGULATORY AFFAIRS 54
      • 3.4.1 U.S. 54
      • 3.4.2 EUROPE 55
      • 3.4.3 CHINA 56
      • 3.4.4 CANADA 57
      • 3.4.5 INDIA 57
    • 3.5 REIMBURSEMENT SCENARIO 58
      • 3.5.1 CPT CODES 60
    • 3.6 PATENT ANALYSIS 81
    • 3.7 TECHNOLOGICAL ADVANCEMENTS 83
      • 3.7.1 INTRODUCTION 83
      • 3.7.2 MINIATURIZATION 84
      • 3.7.3 WIRELESS MICRO- CURRENT STIMULATION 85
      • 3.7.4 WEARABLE PAIN MANAGEMENT TECHNOLOGY 86
      • 3.7.5 MULTI-POINT PACING TECHNOLOGY 86
      • 3.7.6 INTRANASAL TEAR NEUROSTIMULATOR 87
    • 3.8 UPCOMING TECHNOLOGY AND PRODUCT LAUNCH 88
    • 3.9 FUNDING SCENARIO 109
    • 3.10 ELECTROCEUTICAL DEVICES - DEALS 111
    • 3.11 CLINICAL TRIAL DATA 113
    • 3.12 PORTER’S FIVE FORCE ANALYSIS 130
      • 3.12.1 THREAT OF NEW ENTRANTS 132
      • 3.12.2 THREAT OF SUBSTITUTES 132
      • 3.12.3 BARGAINING POWER OF SUPPLIERS 133
      • 3.12.4 BARGAINING POWER OF BUYERS 133
      • 3.12.5 RIVALRY AMONG EXISTING COMPETITORS 134
    • 3.13 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 135

    4 ELECTROCEUTICAL DEVICES GLOBAL MARKET, BY TECHNOLOGY 138

    • 4.1 INTRODUCTION 138
      • 4.1.1 INTERNAL ELECTROCEUTICALS 141
        • 4.1.1.1 Spinal Cord Stimulation (SCS) 146
        • 4.1.1.2 Deep Brain Stimulation (DBS) 149
        • 4.1.1.3 Vagus Nerve Stimulation (VNS) 152
        • 4.1.1.4 Sacral Nerve Stimulation(SNS) 155
        • 4.1.1.5 Internal pacemakers 158
        • 4.1.1.6 Implantable Cardioverter Defibrillator (ICDS) 161
        • 4.1.1.7 Electric Acoustic Stimulation(EAS) 164
        • 4.1.1.8 Others 167
        • 4.1.1.8.1 Gastric Electric Stimulation (GES) 170
        • 4.1.1.8.2 Respiratory Electrical Stimulation (RES)/

        Phrenic Nerve Stimulation 171

        • 4.1.2 EXTERNAL ELECTROCEUTICALS 172
          • 4.1.2.1 Transcutaneous Electrical Nerve Stimulation (TENS) 177
          • 4.1.2.2 External pacemakers 180
          • 4.1.2.3 External & wearable defibrillators 183
          • 4.1.2.4 Others 186
          • 4.1.2.4.1 Tumor Treating Fields(TTFIELDS) 189
          • 4.1.2.4.2 Micro-Current Stimulation 190

          5 ELECTROCEUTICAL DEVICES GLOBAL MARKET, BY APPLICATIONS 191

          • 5.1 INTRODUCTION 191
          • 5.2 PAIN MANAGEMENT 195
            • 5.2.1 CHRONIC PAIN 200
            • 5.2.2 FAILED BACK SURGERY SYNDROME (FBSS) 202
            • 5.2.3 MIGRAINE 204
            • 5.2.4 ISCHEMIA 206
          • 5.3 CENTRAL NERVOUS SYSTEM 208
            • 5.3.1 PARKINSON’S DISEASE 213
            • 5.3.2 ESSENTIAL TREMORS 215
            • 5.3.3 DYSTONIA 217
            • 5.3.4 EPILEPSY OR SEIZURE 219
            • 5.3.5 DEPRESSION 221
            • 5.3.6 OBSESSIVE COMPULSIVE DISORDER (OCD) 223
          • 5.4 GASTROENTEROLOGY AND UROLOGY 225
            • 5.4.1 GASTROPARESIS 230
            • 5.4.2 URINARY INCONTINENCE 232
            • 5.4.3 FAECAL INCONTINENCE 234
          • 5.5 HEARING AID (OTOLOGY) 236
          • 5.6 CARDIOLOGY 239
            • 5.6.1 ATRIAL FIBRILLATION 244
            • 5.6.2 VENTRICULAR FIBRILLATION 247
            • 5.6.3 OTHER CARDIOLOGY 250
          • 5.7 OTHERS 252
            • 5.7.1 BONE GROWTH STIMULATION 256
            • 5.7.2 DIAPHRAGM PACING / RESPIRATORY STIMULATION 258
            • 5.7.3 DIABETES 260
            • 5.7.4 OBESITY 262
            • 5.7.5 WOUND CARE 264
            • 5.7.6 ONCOLOGY 267

          6 ELECTROCEUTICAL DEVICES GLOBAL MARKET, BY END-USERS 269

          • 6.1 INTRODUCTION 269
          • 6.2 HOSPITALS 272
          • 6.3 HOME CARE 275

          7 REGIONAL ANALYSIS 278

          • 7.1 INTRODUCTION 278
          • 7.2 NORTH AMERICA 281
          • 7.3 EUROPE 302
          • 7.4 ASIA - PACIFIC 322
          • 7.5 REST OF THE WORLD 342

          8 COMPETITIVE LANDSCAPE 362

          • 8.1 INTRODUCTION 362
          • 8.2 APPROVALS 364
          • 8.3 NEW PRODUCT LAUNCHES 377
          • 8.4 OTHERS 385
          • 8.5 AGREEMENTS, COLLOBORATIONS & PARTNERSHIP 388
          • 8.6 MERGERS & ACQUISITIONS 391

          9 MAJOR COMPANIES 393

          • 9.1 BIOTRONIK SE & CO.KG 393
            • 9.1.1 OVERVIEW 393
            • 9.1.2 FINANCIALS 394
            • 9.1.3 PRODUCT PORTFOLIO 394
            • 9.1.4 KEY DEVELOPMENTS 395
            • 9.1.5 BUSINESS STRATEGY 398
            • 9.1.6 SWOT ANALYSIS 399
          • 9.2 BOSTON SCIENTIFIC CORPOARTION 400
            • 9.2.1 OVERVIEW 400
            • 9.2.2 FINANCIALS 401
            • 9.2.3 PRODUCT PORTFOLIO 406
            • 9.2.4 KEY DEVELOPMENTS 407
            • 9.2.5 BUSINESS STRATEGY 410
            • 9.2.6 SWOT ANALYSIS 411
          • 9.3 COCHLEAR LTD. 412
            • 9.3.1 OVERVIEW 412
            • 9.3.2 FINANCIALS 413
            • 9.3.3 PRODUCT PORTFOLIO 416
            • 9.3.4 KEY DEVELOPMENTS 416
            • 9.3.5 BUSINESS STRATEGY 418
            • 9.3.6 SWOT ANALYSIS 419
          • 9.4 DJO GLOBAL, INC. 420
            • 9.4.1 OVERVIEW 420
            • 9.4.2 FINANCIALS 421
            • 9.4.3 PRODUCT PORTFOLIO 424
            • 9.4.4 KEY DEVELOPMENTS 425
            • 9.4.5 BUSINESS STRATEGY 425
            • 9.4.6 SWOT ANALYSIS 426
          • 9.5 ENTEROMEDICS INC. 427
            • 9.5.1 OVERVIEW 427
            • 9.5.2 FINANCIALS 428
            • 9.5.3 PRODUCT PORTFOLIO 428
            • 9.5.4 KEY DEVELOPMENTS 429
            • 9.5.5 BUSINESS STRATEGY 430
            • 9.5.6 SWOT ANALYSIS 431
          • 9.6 LIVANOVA 432
            • 9.6.1 OVERVIEW 432
            • 9.6.2 FINANCIALS 433
            • 9.6.3 PRODUCT PORTFOLIO 436
            • 9.6.4 KEY DEVELOPMENTS 437
            • 9.6.5 BUSINESS STRATEGY 438
            • 9.6.6 SWOT ANALYSIS 439
          • 9.7 MEDTRONIC, PLC 440
            • 9.7.1 OVERVIEW 440
            • 9.7.2 FINANCIALS 441
            • 9.7.3 PRODUCT PORTFOLIO 446
            • 9.7.4 KEY DEVELOPMENTS 448
            • 9.7.5 BUSINESS STRATEGY 454
            • 9.7.6 SWOT ANALYSIS 455
          • 9.8 NEUROMETRIX, INC 456
            • 9.8.1 OVERVIEW 456
            • 9.8.2 FINANCIALS 457
            • 9.8.3 PRODUCT PORTFOLIO 459
            • 9.8.4 KEY DEVELOPMENTS 460
            • 9.8.5 BUSINESS STRATEGY 464
            • 9.8.6 SWOT ANALYSIS 465
          • 9.9 NEVRO CORP. 466
            • 9.9.1 OVERVIEW 466
            • 9.9.2 FINANCIALS 467
            • 9.9.3 PRODUCT PORTFOLIO 468
            • 9.9.4 KEY DEVELOPMENTS 469
            • 9.9.5 BUSINESS STRATEGY 470
            • 9.9.6 SWOT ANALYSIS 471
          • 9.10 PHILIPS HEALTHCARE 472
            • 9.10.1 OVERVIEW 472
            • 9.10.2 FINANCIALS 473
            • 9.10.3 PRODUCT PORTFOLIO 476
            • 9.10.4 KEY DEVELOPMENTS 476
            • 9.10.5 BUSINESS STRATEGY 477
            • 9.10.6 SWOT ANALYSIS 478
          • 9.11 ST.JUDE MEDICAL, INC. 479
            • 9.11.1 OVERVIEW 479
            • 9.11.2 FINANCIALS 480
            • 9.11.3 PRODUCT PORTFOLIO 483
            • 9.11.4 KEY DEVELOPMENTS 485
            • 9.11.5 BUSINESS STRATEGY 490

    The electroceuticals technology utilizes devices that bring about a change in the nervous system by modulating brain activity. The treatment delivered by neurostimulation devices brings about life changing transformation in patients who fail to respond to traditional approaches. The opportunities to development new therapies for a wide variety of neurological and psychological conditions are attracting a lot of companies, startups and investments. According to IQ4I analysis, the global electroceutical devices market is expected to grow at a double digit CAGR from 2015 to 2022. Factors driving the electroceutical devices market include, projected increase in patients with chronic pain, neurological diseases, psychiatric conditions, cardiology conditions, improvements in technology such as miniaturization, better battery technology, wearable, wireless micro-current stimulation are all contributing to growth of electroceutical devices market whereas shocking areas of neural tissue to stimulate the desired response, electrical devices have been clunky and imprecise, mode of action is not known so basically it is a trial and error method etc are the factors hampering the market growth. Advancement of technology with its wide application areas shows that electroceutical devices market has vast opportunities in the coming years.
    Electroceutical devices market is segmented on the basis of technology as internal and external electroceutical devices. The internal electroceutical devices is classified into Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS), Pacemakers, Implantable Cardioverter Defibrillator (ICD), Cochlear Implants and Others with Gastric Electrical Stimulation (GES) and Respiratory Electrical Stimulation (RES)/Phrenic Nerve Stimulation (PNS). The external electroceutical devices are classified as Transcutaneous External Nerve Stimulation (TENS), External Pacemakers, External Defibrillators and Others (Tumour Treating Fields (TTF), Micro-current stimulation).
    Based on the application the electroceutical devices market is segmented into Pain management, Central Nervous System (CNS), Gastroenterology/Urology, Hearing aids, Cardiology and other applications. Based on end-users the market is segmented into hospitals and home care.
    North America accounts for the highest market share followed by Europe. The steep rise in ageing population, advancement in technology, awareness of people and favorable government policies makes U.S. the leader of electroceutical devices market. However, Asian countries especially India and China are the fast growing regions with its growing demand for electroceutical devices.
    Major players in Electroceuticals devices market include Boston Scientific (U.S.), St. Jude Medical (U.S), St. Jude Medical (U.S.), Cogentix medical (U.S.), LivaNova (U.K.), Biotronik (Germany), NeuroMetrix (U.S.), Nevro Corporation (U.S.) etc.
    The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

    Buy now